Target intelligence / Profile preview

Equilibrative nucleoside transporter 4 (ENT4)

Target
ENT4
Molecular classification
Transporter, Solute carrier family protein (SLC29), Equilibrative nucleoside transporter
01

Overview

Equilibrative nucleoside transporter 4 (ENT4, also known as plasma membrane monoamine transporter [PMAT], SLC29A4) is a member of the SLC29 family of solute transporters characterized by 11 transmembrane domains and is primarily localized to the plasma membrane. Unlike other ENTs, ENT4 is distinct for its roles as both a pH-dependent adenosine transporter and a polyspecific organic cation/monoamine transporter. At neutral pH, it efficiently transports multiple biogenic amines, while under acidic conditions, such as those found in tissue ischemia or tumor microenvironments, it mediates the transport of adenosine and analogues like 2-chloroadenosine. ENT4 is transcriptionally upregulated in certain cancers (e.g., DSRCT), where it may support tumor growth by facilitating cellular adaptation to hypoxia and acidity. ENT4 plays important physiological roles in nucleoside salvage pathways, regulation of extracellular adenosine (with implications for ischemia protection), and neurotransmitter regulation.

Other names
Plasma membrane monoamine transporterPMATSLC29A4
02

Mechanism of action

Facilitation/diffusion of nucleosides and monoamines across the plasma membrane down their concentration gradient (equilibrative, pH-dependent for adenosine transport). At neutral pH, acts as a polyspecific organic cation/monoamine transporter; at acidic pH, acts as an adenosine/adenosine analogue transporter

03

Biological functions

Nucleoside transportAdenosine transport (especially under acidic conditions)Monoamine transport (biogenic amines)Regulation of extracellular adenosine concentrations
04

Disease associations

Cancer (implicated in desmoplastic small round cell tumor [DSRCT] and suggested to support tumor cell adaptation to hypoxic/acidic microenvironments)Cardiovascular disease (potential protective role in ischemic tissues)Other (potential involvement in diseases where adenosine or monoamine regulation is relevant)
05

Safety considerations

Specific safety concerns or therapeutic challenges are not established, but overactivity or inhibition could alter extracellular adenosine or monoamine pools, with possible consequences in cardiovascular, neural, or tumor settings.
06

Interacting drugs

2-chloroadenosine (adenosine analogue, substrate)

1 more in the full profile.

07

Biomarkers

ENT4/PMAT expression in certain cancers (e.g., DSRCT)Potential as a biomarker in tissues subjected to ischemia or acidic microenvironment (research context)

Beyond the preview

Go deeper on Equilibrative nucleoside transporter 4 (ENT4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Equilibrative nucleoside transporter 4 (ENT4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call